Department of Microbiology and Immunology, Sidney Kimmel Medical College,Thomas Jefferson University, Philadelphia, Pennsylvania 19107; email:
Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892.
Annu Rev Med. 2017 Jan 14;68:371-386. doi: 10.1146/annurev-med-051215-030919. Epub 2016 Sep 28.
Long-term control of viral outbreaks requires the use of vaccines to impart acquired resistance and ensuing protection. In the wake of an epidemic, established immunity against a particular disease can limit spread and significantly decrease mortality. Creation of a safe and efficacious vaccine against Ebola virus (EBOV) has proven elusive so far, but various inventive strategies are now being employed to counteract the threat of outbreaks caused by EBOV and related filoviruses. Here, we present a current overview of progress in the field of Ebola virus vaccine development.
长期控制病毒爆发需要使用疫苗来赋予获得性抗性和随之而来的保护。在疫情爆发后，对特定疾病的既定免疫力可以限制传播并显著降低死亡率。到目前为止，针对埃博拉病毒（EBOV）创建安全有效的疫苗一直难以实现，但现在正在采用各种创造性策略来应对由 EBOV 和相关丝状病毒引起的爆发威胁。在这里，我们介绍了埃博拉病毒疫苗开发领域的最新进展概述。
